Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PRKACA | P17612 | 2/20 | 0.33 |
| ▸ | PRKACG | P22612 | 2/20 | 0.33 |
| ▸ | PRKACB | P22694 | 2/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7124012 | 0.82 | — | — | |
| SCHEMBL7124015 | 0.81 | MAPKAPK2 (0.32) | LMNAMAPTPRKACAPRKACGPRKACB | |
| SCHEMBL20424920 | 0.78 | XDH (0.32) | XDH | |
| SCHEMBL31467831 | 0.78 | TRPV4 (0.36) | XDH | |
| SCHEMBL24819189 | 0.73 | MAPT (0.39) | LMNAMAPTCYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL4605739 | 0.73 | LMNA (0.36) | LMNAMAPTALDH1A1 | |
| SCHEMBL21603450 | 0.73 | LMNA (0.36) | LMNAMAPTCYP3A4ALDH1A1 | |
| SCHEMBL31355576 | 0.73 | LMNA (0.36) | LMNAMAPTALDH1A1 | |
| SCHEMBL24104577 | 0.73 | LMNA (0.36) | LMNAMAPT | |
| SCHEMBL31115520 | 0.73 | LMNA (0.36) | LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113880866-B | Aza-tetrahydronaphthyridine compound, preparation method thereof, pharmaceutical composition and application thereof | 上海维申医药有限公司 | 2022-09-27 | — | — | CN | disclosed |
| CN-113880866-A | Aza-tetrahydronaphthyridine compound, preparation method thereof, pharmaceutical composition and application thereof | 上海维申医药有限公司 | 2022-01-04 | — | — | CN | disclosed |
| US-10961213-B2 | Process for preparation of benzylic amides | BASF SE (DE) | 2021-03-30 | — | — | US | disclosed |
| WO-2018137959-A1 | PROCESS FOR PREPARATION OF BENZYLIC AMIDES | BASF SE (DE) | 2018-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961213-B2 | Process for preparation of benzylic amides | CYP2F1, BBOX1, F12 | LMNA 1118/4885MAPT 4473/4885PRKACA 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.